ES2166779T3 - Complejos inmunogenicos del hiv. - Google Patents

Complejos inmunogenicos del hiv.

Info

Publication number
ES2166779T3
ES2166779T3 ES94917313T ES94917313T ES2166779T3 ES 2166779 T3 ES2166779 T3 ES 2166779T3 ES 94917313 T ES94917313 T ES 94917313T ES 94917313 T ES94917313 T ES 94917313T ES 2166779 T3 ES2166779 T3 ES 2166779T3
Authority
ES
Spain
Prior art keywords
hiv
immunogenic complexes
complex
vaccine
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94917313T
Other languages
English (en)
Inventor
Anthony Louis Devico
Ranajit Pal
Mangalasseril G Sarngadharan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux Inc
Original Assignee
Biomerieux Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux Inc filed Critical Biomerieux Inc
Application granted granted Critical
Publication of ES2166779T3 publication Critical patent/ES2166779T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE PRESENTA UNA VACUNA Y UN METODO PARA ELEVAR LA NEUTRALIZACION DE ANTICUERPOS CONTRA LA INFECCION POR HIV. LA VACUNA COMPRENDE UN COMPLEJO DE GP120 COVALENTEMENTE UNIDO CON CD4 O A CONCANAVALINA DE SUCCINIL A. TAMBIEN SE HAN DESCUBIERTO PRUEBAS INMUNOLOGICAS QUE UTILIZAN EL COMPLEJO O LOS ANTICUERPOS PARA EL MISMO PARA LA DETECCION DE INFECCIONES POR HIV.
ES94917313T 1993-05-07 1994-05-06 Complejos inmunogenicos del hiv. Expired - Lifetime ES2166779T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6092693A 1993-05-07 1993-05-07

Publications (1)

Publication Number Publication Date
ES2166779T3 true ES2166779T3 (es) 2002-05-01

Family

ID=22032603

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94917313T Expired - Lifetime ES2166779T3 (es) 1993-05-07 1994-05-06 Complejos inmunogenicos del hiv.

Country Status (10)

Country Link
US (6) US5843454A (es)
EP (1) EP0699077B1 (es)
JP (1) JPH08510246A (es)
AT (1) ATE207760T1 (es)
AU (1) AU680916B2 (es)
DE (1) DE69428896T2 (es)
DK (1) DK0699077T3 (es)
ES (1) ES2166779T3 (es)
PT (1) PT699077E (es)
WO (1) WO1994026305A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165710A (en) * 1989-10-23 2000-12-26 Robinson; James E. Method for immobilizing viral glycoproteins for use in solid-phase immunoassays
US20040076636A1 (en) * 1993-05-07 2004-04-22 Ranajit Pal HIV immunogenic complexes
US20060159688A1 (en) * 1996-05-15 2006-07-20 Ragupathy Madiyalakan Method for diagnosing efficacy of xenotypic antibody therapy
US8038994B2 (en) * 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
SI0910407T1 (en) * 1996-05-15 2003-10-31 Altarex Corp. Method and composition for reconforming multi-epitopic antigens to initiate an immune response
WO1998000535A2 (en) * 1996-06-28 1998-01-08 Dana-Farber Cancer Institute Method for inhibiting hiv-1 infection, drug screens, and methods of diagnosis and prognosis of susceptibility to hiv infection
US7063850B1 (en) * 1998-12-22 2006-06-20 University Of Tennessee Research Foundation Protective antigen of group A Streptococci
FR2789590B1 (fr) * 1999-02-15 2003-01-17 Inst Rech Developpement Ird Compositions immunogenes utilisables comme vaccins
US7115262B1 (en) 1999-03-16 2006-10-03 The United States Of America As Represented By The Department Of Health And Human Services Chimeric protein for prevention and treatment of HIV infection
PT1137786E (pt) * 1999-10-08 2007-07-13 Univ Maryland Biotech Inst Quimeras de proteína do invólucro/receptor de vírus e métodos de utilização.
US6908612B2 (en) 1999-10-08 2005-06-21 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
US7311920B1 (en) 1999-10-08 2007-12-25 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
FR2799974B1 (fr) * 1999-10-25 2001-11-30 Aventis Pasteur Complexe deglycosyle proteine env/cd4 et son utilisation pour la vaccination contre le vih
US6503736B1 (en) * 1999-11-12 2003-01-07 BIOMéRIEUX, INC. Antibodies to crosslinkers and methods for using the same
CN1505528A (zh) 2000-09-22 2004-06-16 �ſ���ѧ��˾ 包含结合hiv包膜蛋白的配体的免疫原
US7033593B2 (en) * 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
CA2431212A1 (en) * 2000-12-27 2002-07-25 Richard T. Wyatt Immunogenic proteoliposomes, and uses thereof
US20050031619A1 (en) * 2001-03-21 2005-02-10 Nicodemus Christopher F. Therapeutic compositions that alter the immune response
CA2463931A1 (en) * 2001-10-16 2003-04-24 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes
WO2003086041A2 (en) * 2002-04-11 2003-10-23 Altarex Medical Corporation Binding agents and their use in targeting tumor cells
CA2485120C (en) * 2002-05-06 2013-02-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
US7803913B2 (en) * 2002-05-06 2010-09-28 The United States Of America As Represented By The Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
WO2004037847A2 (en) * 2002-05-07 2004-05-06 Chiron Corporation Hiv envelope-cd4 complexes and hybrids
JPWO2004002511A1 (ja) * 2002-06-28 2005-10-27 扶桑薬品工業株式会社 抗ｈｉｖ剤
WO2004002500A1 (en) 2002-06-28 2004-01-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
EP2374811A1 (en) * 2002-07-23 2011-10-12 Duke University IgG Fc/HIV-gp120/c3d fusion protein
JP4038679B2 (ja) * 2003-05-13 2008-01-30 住友電気工業株式会社 半導体レーザーバーの固定用治具
US8637234B2 (en) * 2004-04-16 2014-01-28 Uab Research Foundation Molecular scaffolds for HIV-1 epitopes
CA2569562C (en) 2004-06-08 2013-12-03 Vega Masignani Fusion proteins comprising cd4 minimal modules and methods of use thereof
WO2006026097A2 (en) * 2004-08-25 2006-03-09 Vijay Ramakrishnan Pegylation of antibodies against hiv
WO2006044410A2 (en) * 2004-10-14 2006-04-27 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services A32 monoclonal antibody fusion proteins for use as hiv inhibitors and vaccines
US20070292390A1 (en) * 2004-10-29 2007-12-20 Dimitrov Dimiter S Broadly Cross-Reactive Hiv-1 Neutralizing Human Monoclonal Antibodies
WO2006084179A2 (en) 2005-02-03 2006-08-10 Novartis Vaccines And Diagnostics Inc. Hiv tat-cd4 hybried molecules and methods of use thereof
WO2006091455A2 (en) * 2005-02-18 2006-08-31 Uab Research Foundation Molecular scaffolds for hiv-1 immunogens
CA2623197A1 (en) * 2005-09-22 2007-03-29 Prosci Incorporated Glycosylated polypeptides produced in yeast mutants and methods of use thereof
US20100104580A1 (en) * 2008-09-03 2010-04-29 Philadelphia Health & Education Corporation D/B/A Altered Immunogenic Landscape in HIV-1 Envelope Proteins
US20110212119A1 (en) * 2008-10-31 2011-09-01 Proteonova, Inc. Methods for making hiv vaccines and related compositions
US8340810B2 (en) * 2008-10-31 2012-12-25 Spectra Logic Corp. Robotic storage library with queued move instructions and method of queuing such instructions
WO2011097511A1 (en) 2010-02-05 2011-08-11 The United States Of America, As Represented By The Secretary Department Of Health & Human Services REGULATORY B CELLS (tBREGS) AND THEIR USE
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CN116948019A (zh) * 2011-05-17 2023-10-27 洛克菲勒大学 人类免疫缺陷病毒中和抗体及其使用方法
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
WO2013188870A2 (en) * 2012-06-15 2013-12-19 Beth Israel Deaconess Medical Center, Inc. IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
AU2014352638B2 (en) 2013-11-25 2018-08-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors to control HIV infection
WO2015120440A2 (en) * 2014-02-10 2015-08-13 Dana-Farber Cancer Institute, Inc. Cd4-mimetic small molecules sensitize human immunodeficiency virus to vaccine-elicited antibodies
US9975848B2 (en) 2014-08-13 2018-05-22 The Trustees Of The University Of Pennsylvania Inhibitors of HIV-1 entry and methods of use thereof
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL93599A0 (en) * 1989-03-03 1990-12-23 Microgenesys Inc Kit and/or composition for the prevention or treatment of aids
EP0550516A1 (en) * 1990-09-28 1993-07-14 Hospital For Joint Diseases Method for inhibiting the infectivity of human immunodeficiency virus

Also Published As

Publication number Publication date
EP0699077A1 (en) 1996-03-06
US5843454A (en) 1998-12-01
US6465172B1 (en) 2002-10-15
ATE207760T1 (de) 2001-11-15
US5518723A (en) 1996-05-21
DK0699077T3 (da) 2002-01-21
PT699077E (pt) 2002-04-29
US6030772A (en) 2000-02-29
US20030039663A1 (en) 2003-02-27
AU6907394A (en) 1994-12-12
WO1994026305A1 (en) 1994-11-24
AU680916B2 (en) 1997-08-14
US6328973B1 (en) 2001-12-11
DE69428896T2 (de) 2002-06-20
EP0699077B1 (en) 2001-10-31
DE69428896D1 (de) 2001-12-06
JPH08510246A (ja) 1996-10-29

Similar Documents

Publication Publication Date Title
CY1123667T1 (el) Παρασκευασμα ανοσοσφαιρινης και μεθοδος παρασκευης αυτου
ES2098029T3 (es) Vacunas de hepatitis que contienen monofosforil lipido a 3-o-desacilado.
ES2176232T3 (es) Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.
ES2140076T3 (es) Vacunas que contienen una saponina y un esterol.
PT699077E (pt) Complexo imunogenico de hiv
FI903292A0 (fi) T-cellepitop som baerarmolekyler foer konjugerade vacciner.
MXPA02007413A (es) Vacuna para la inmunizacion profilactica o terapeutica contra el vih.
ES2125233T3 (es) Tratamiento de las infecciones retrovirales humanas con 2',3'-didesoxiinosina.
AU5821000A (en) Vaccine
ES2118109T3 (es) Antigenos polisacaridos de streptococcus pneumoniae.
YU28392A (sh) Vakcina koja sadrži glikoprotein d i 3deacilovani monofosforil lipid a
ES2530769T3 (es) Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
EP2302059A8 (en) Modifications of hiv Env, Gag, and Pol enhance immunogenicity for genetic immunization
ES2084174T3 (es) Productos y procesos para el tratamiento del conducto alimentario.
GB2255093A (en) Hiv-1 core protein fragments
AR114627A1 (es) Composición inmunogénica
ES2074062T3 (es) Inmunoensayo para antigenos hiv-1 que utilizan fragmentos de f(ab')2 como sonda.
ES2062330T3 (es) Conjugados.
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
FI934133A7 (fi) gp160:n johdannaiset ja gp160:een tai sen johdannaiseen perustuvat rok otteet, jotka sisältävät apuainetta
ATE148918T1 (de) Für die co4-bindende domäne von hiv spezifische antikörper
NL155014B (nl) Werkwijze voor de bereiding van farmaceutische preparaten, gevormde preparaten, alsmede werkwijze voor de bereiding van daarvoor geschikte farmacologisch werkzame uracillen met op de 6-plaats een zijketen met daarin een n-fenylpiperazinoalkyl-groep.
SE9604581D0 (sv) An agent against cancer and virus infections
IT1223679B (it) Procedimento e dispositivo per sud dividere in pila parziali conteggiate una pila di articoli pieghevoli particolarmente per tessuti
ES2056075T3 (es) Anticuerpos monoclonales para regiones especificas antigenicas del virus de inmunodeficiencia humana y procedimientos para su uso.